In particular, recurrence scores obtained using the Oncotype Dx 21-gene assay guide the selection of patients with luminal (HR-positive/HER-2–negative) breast cancer who will benefit from AC (16–18). This evidence concerns the gene ERBB2 and breast carcinoma.